Thinking Beyond Wet Age-Related Macular Degeneration
نویسندگان
چکیده
منابع مشابه
Wet Age Related Macular Degeneration
Age related macular degeneration (AMD) is the leading cause of blindness in the developed countries. Approximately 8 million people in America have AMD and the number of advanced AMD is likely to rise by 50% by year 2020 due to the projected increase in the number of elderly people (Friedman et al., 2004). AMD is a condition of significant morbidity in terms of both physical and mental health (...
متن کاملImaging of Wet Age-Related Macular Degeneration
All images are acquired on a Spectralis device from Heidelberg Engineering. Image courtesy of Dr. (med) Ke-nan Damer, Birmingham Midlands Eye Centre, Sandwell and West Birmingham NHS Trust. Fig. 1. a Shows the macula of a left eye with reduced foveal reflectivity on the infra-red picture, which is due to intra-retinal fluid caused by choroidal neovascularization (CNV) related to wet AMD. In b ,...
متن کاملAge-related macular degeneration: Beyond anti-angiogenesis
Recently, anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration have been developed. These agents, originally developed for their anti-angiogenic mechanism of action, probably also work through an anti-permeability effect in preventing or reducing the amount of leakage from submacular neovascular tissue. Other treatment modalities include laser photo...
متن کاملThe treatment of wet age-related macular degeneration.
BACKGROUND Age-related macular degeneration (AMD) is a progressive disease affecting the macula, the area of the retina that has the highest visual acuity. It can progress to geographic atrophy or choroidal neovascularization. METHOD Selective literature review. RESULTS The authors discuss the results of therapeutic trials and the treatment recommendations of the ophthalmological societies....
متن کاملIndividualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
Individualized treatment regimens may reduce patient burden with satisfactory patient outcomes in neovascular age-related macular degeneration. Intravitreal anti-VEGF drugs are the current gold standard. Fixed monthly injections offer the best visual outcome but this regimen is not commonly followed outside clinical trials. A PRN regimen requires monthly visits where the patient is treated in t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Delhi Journal of Ophthalmology
سال: 2016
ISSN: 0972-0200
DOI: 10.7869/djo.174